Home > News > Headline News


Please Note

Some news stories may require you to register or sign in.  MedPage, for example, has an easy and free subscription form that only needs to be completed once--well worth the effort to access their timely and important articles.

Click on title to read the full article.

Epigenetic regulation of metastatic breast cancer progression may guide prognosis and future therapy

January 7, 2016

By Medical Express

Researchers have identified a gene called serum deprivation response (SDPR) and the mechanisms by which this gene is down-regulated, or silenced, in breast cancer cells promoting tumor spread.

Immunotherapy Is Game-Changer for Oncology

January 1, 2016

By Medpage

(Medpage requires a one-time free registration--well worth doing)New immunotherapy drugs to treat a wide swathe of cancers, are the game changers of 2015, according to dozens of oncologists who responded to MedPage Today.

Carboplatin Role in Triple-Negative Breast Cancer Unresolved

December 15, 2015

By MedPag Today Charles Bankhead

The relationship between pathologic complete response and survival in triple negative breast cancer remained murky as two different randomized studies arrived at somewhat different conclusions.

Pembrolizumab Continues to Show Promise in Breast Cancer

December 13, 2015

By OncLive

"Based on these data, we believe that further investigation of immune therapies in ER+/HER- breast cancer, particularly using combination therapies that can expand the T-cell compartment, is warranted," lead researcher Hope S. Rugo, MD

Small Study Shows Immunotherapy Effective in Metastatic Breast Cancer Subset

December 11, 2015

By Cure Today Silas Inman

Treatment with the immunotherapy avelumab demonstrated promising overall response rates (ORR) for patients with PD-L1–positive metastatic breast cancer, particularly for those with triple-negative disease.

Recent Clinical Findings for Targeting CDK 4/6 in Breast Cancer

December 11, 2015

By Cancer Therapy Advisor Bryant Furlow

Palbociclib in combination with letrozole and now fulvestrant demonstrated significant clinical activity over endocrine therapy alone in advanced ER+ breast cancer and is the first approved CDK inhibitor,” Dr Finn said. “The combination was generally well tolerated, with uncomplicated neutropenia as the most frequent adverse event.”

ASCO Clinical Practice Guideline: Use of Biomarkers to Guide Systemic Therapy for Women With Metastatic Breast Cancer

December 11, 2015

By Matthew Stenger The ASCO Post

ASCO has issued a clinical practice guideline on the use of biomarkers to guide decisions on systemic therapy in women with metastatic breast cancer.

POINT: HER2-Targeted Combinations in Advanced HER2-Positive Breast Cancer

December 10, 2015

By Shom Goel, MD and Eric P. Winer, MD

The primary goals when treating patients with metastatic breast cancer are to improve both duration and quality of life.

Clinical trial explores treatment for metastases while continuing overall breast cancer therapy

December 9, 2015

By Medical Express

An ongoing phase IIR/III clinical trial presented at the 2015 San Antonio Breast Cancer Symposium seeks to answer an important question in the treatment of early metastatic breast cancer: Should surgery or stereotactic body radiation be used...

Women with Stage 4 breast cancer survive longer with surgery, study shows

December 4, 2015

By Lenny Bernstein, Washington Post

Over the past few decades, as breast cancer has increasingly been treated as a systemic disease, the number of surgeries performed on the most serious cases has plummeted.
 < 1 2 3 4 5 >  Last ›